Singapore markets closed

BCRX Jan 2025 22.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.22000.0000 (0.00%)
As of 03:19PM EDT. Market open.
Full screen
Previous close0.2200
Open0.2000
Bid0.0000
Ask0.2500
Strike22.00
Expiry date2025-01-17
Day's range0.2000 - 0.2200
Contract rangeN/A
Volume5
Open interest174
  • GlobeNewswire

    BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

    RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. “We are excited to announce that ORLADEYO is now approved in the region’s largest market, following the positive regulatory decisions w

  • Insider Monkey

    12 Best Depressed Stocks To Buy in 2024

    In this article, we will take a detailed look at the 12 Best Depressed Stocks To Buy in 2024. For a quick overview of the 5 such stocks, read our article 5 Best Depressed Stocks To Buy in 2024. JPMorgan Chief Jamie Dimon, in his latest letter to shareholders, has warned that the real odds of soft landing a quite […]

  • GlobeNewswire

    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 43,975 shares, and restricted stock units (RSUs) covering an aggregate of 30,625 shares, of BioCryst common stock. The options and RSUs were granted as of March 29, 2024, as inducements material to each employee entering into employ